STLN
Starling Oncology, Inc.
STLN lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
STLN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Stable | |
| Unavailable |
STLN's revenue is currently healthy, and its profitability and cash flow are stable. There isn't enough data to rate its balance sheet.
STLN PE Valuation
STLN has no meaningful PE right now: it lost money over the past year.
STLN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect STLN's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
STLN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.27 | +$0.37 |
| Q2 2026 | -$0.28 | +$0.40 |
| Q1 2026 | -$0.35 | +$0.35 |
| Q4 2025 | -$0.54 | +$0.17 |
| Q3 2025 | -$0.64 | +$0.14 |
| Q2 2025 | -$0.68 | +$0.11 |
| Q1 2025 | -$0.70 | +$0.11 |
| Q4 2024 | -$0.71 | +$0.21 |
STLN is still losing money, but far less than before: $0.27 per share over the past year, against $0.92 at its worst in late 2023.
STLN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $169.8M | +24% |
| Q2 2026 | $161.3M | +35% |
| Q1 2026 | $147.4M | +41% |
| Q4 2025 | $142M | +42% |
| Q3 2025 | $136.6M | +37% |
| Q2 2025 | $119.8M | +22% |
| Q1 2025 | $104.4M | +10% |
| Q4 2024 | $100.3M | +17% |
STLN's revenue has grown year over year every quarter since early 2023: $170M last quarter, up 24% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1.8% | +4.1 points |
| Q2 2026 | -2.9% | +6.5 points |
| Q1 2026 | -4.4% | +5.1 points |
| Q4 2025 | -4.9% | +7 points |
| Q3 2025 | -5.9% | +8 points |
| Q2 2025 | -9.4% | +7.2 points |
| Q1 2025 | -9.5% | +9.5 points |
| Q4 2024 | -12% | +5.9 points |
STLN's operating margin was −1.8% last quarter, up 4.1 points from the same quarter a year ago, near the top of its range since 2022.
STLN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.9M | +$22.1M |
| Q2 2026 | $11M | +$22.4M |
| Q1 2026 | -$3.3M | +$2.1M |
| Q4 2025 | $2.2M | -3.2% |
| Q3 2025 | -$13.2M | -1184% |
| Q2 2025 | -$11.4M | +$6.1M |
| Q1 2025 | -$5.3M | +$11.2M |
| Q4 2024 | $2.2M | +$7M |
STLN's free cash flow has turned positive after six years mostly in the red: $19M over the past year.
STLN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.6% | +1.7M shares |
| 1 year | +7.4% | +7.3M shares |
| 3 years | +43% | +31.3M shares |
| 5 years | +1721% | +99M shares |
STLN has 105M diluted shares, up 7.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q4 2023 | — |
| Q3 2023 | $125,000 |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $9M |
STLN Net Leverage
STLN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
STLN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.7 | Neutral |
| Stochastic | 31.0 | Neutral |
STLN's weekly RSI is 37 (neutral) and its Stochastic is 31 (neutral).
STLN PE vs Healthcare Sector
STLN has no meaningful PE right now: it lost money over the past year.
STLN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.83 | 36% below |
| 20 week MA | $5.88 | 36% below |
| 50 week MA | $4.53 | 17% below |
| 100 week MA | $3.49 | 7.4% above |
| 200 week MA | $2.25 | 67% above |
STLN has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 67% above its 200-week average.
STLN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.84 | $10.8 | +9.8% |
| 2021 | $10.8 | $10.4 | -3.3% |
| 2022 | $10.4 | $1.60 | -85% |
| 2023 | $1.60 | $2.04 | +27% |
| 2024 | $2.04 | $0.32 | -84% |
| 2025 | $0.32 | $3.64 | +1038% |
| 2026 YTD | $3.64 | $3.75 | +3% |
STLN's yearly returns have swung widely, from +1038% in 2025 to −85% in 2022. It's up 3% so far in 2026.